Drug-induced atrial fibrillation

Bibliography

• Fuster V, Ryden LE, Cannom DS, 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2011;123:e269-367
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• van der Hooft CS, Heeringa J, van Herpen G, Drug-induced atrial fibrillation. J Am Coll Cardiol 2004;44:2117-24
   PubMed Web of Science ®Google Scholar
• Nattel S, Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Nishida J, Kato T, Nattel S. Atrial fibrillation pathophysiology. Implications for management. Circulation 2011;124:2264-74
   PubMed Web of Science ®Google Scholar
• Haissaguerre M, Jais P, Shah DC, Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66
   PubMed Web of Science ®Google Scholar
• Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002;105:2753-9
   PubMed Web of Science ®Google Scholar
• De Caterina R, Ruigomez A, Rodriguez LA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med 2010;170:1450-5
   PubMed Web of Science ®Google Scholar
• Schmidt M, Christiansen CF, Mehnert F, Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 2011;343:d3450
   PubMed Web of Science ®Google Scholar
• van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006;166:1016-20
   PubMed Web of Science ®Google Scholar
• Christiansen CF, Christensen S, Mehnert F, Glucocorticoid use and risk of atrial fibrillation or flutter. A population-based, case-control study. Arch Intern Med 2009;169:1677-83
   PubMed Web of Science ®Google Scholar
• Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005;16:360-6
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Kondoh H, Yamamoto Y, Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol 1990;10:231-6
   PubMed Web of Science ®Google Scholar
• Iqbal FM, Beeharilal PS, Sadat K, Steroid induced atrial fibrillation. Compr Ther 2008;34:111-14
   PubMedGoogle Scholar
• Dogukan A, Ilkay E, Poyrazoglu OK, Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferative glomerulonephritis. Acta Med (Hradec Kralove) 2008;51:63-4
   PubMedGoogle Scholar
• Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther 2001;8:303-5
   PubMedGoogle Scholar
• McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 1993;104:622-3
   PubMed Web of Science ®Google Scholar
• Ueda N, Yoshikawa T, Chihara M, Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol 1988;2:29-31
   PubMed Web of Science ®Google Scholar
• Emara MK, Saadet AM. Transient atrial fibrillation in hypertensive patients with thiazide induced hypokalaemia. Postgrad Med J 1986;62:1125-7
   PubMed Web of Science ®Google Scholar
• Fitton A, Benfield P. Dopexamine hydrochloride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 1990;39:308-30
   PubMed Web of Science ®Google Scholar
• Argalious M, Motta P, Khandwala F, “Renal dose” dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005;33:1327-32
   PubMed Web of Science ®Google Scholar
• Burger AJ, Notarianni MP, Aronson D. Safety and efficacy of an accelerated dobutamine stress echocardiography protocol in the evaluation of coronary artery disease. Am J Cardiol 2000;86:825-9
   PubMed Web of Science ®Google Scholar
• Mertes H, Sawada SG, Ryan T, Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography-experience in 1118 patients. Circulation 1993;88:15-19
   PubMed Web of Science ®Google Scholar
• Poldermans D, Fioretti PM, Boersma E, Dobutamine-atropine stress echocardiography in elderly patients unable to perform an exercise test. Hemodynamic characteristics, safety, and prognostic value. Arch Intern Med 1994;154:2681-6
   PubMed Web of Science ®Google Scholar
• Dakik HA, Vempathy H, Verani MS. Tolerance, hemodynamic changes, and safety of dobutamine stress perfusion imaging. J Nucl Cardiol 1996;3:410-14
   PubMed Web of Science ®Google Scholar
• Geleijnse ML, Elhendy A, Fioretti PM, Roelandt JR. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000;36:2017-27
   PubMed Web of Science ®Google Scholar
• Wahl A, Paetsch I, Gollesch A, Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J 2004;25:1230-6
   PubMed Web of Science ®Google Scholar
• Carasso S, Sandach A, Kuperstein R, Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000;36:2017-27
   PubMed Web of Science ®Google Scholar
• Kane GC, Hepinstall MJ, Kidd GM, Safety of stress echocardiography supervised by registered nurses: results of a 2-year audit of 15,404 patients. J Am Soc Echocardiogr 2008;21:337-41
   PubMed Web of Science ®Google Scholar
• Poldermans D, Fioretti PM, Boersma E, Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease. Am J Cardiol 1994;73:456-9
   PubMed Web of Science ®Google Scholar
• Elhendy A, Valkema R, van Domburg RT, Safety of dobutamine-atropine stress myocardial perfusion scintigraphy. J Nucl Med 1998;39:1662-6
   PubMed Web of Science ®Google Scholar
• Wirtz CE. Sustained atrial fibrillation after dobutamine stress echocardiography in an older patient with left atrial enlargement. West J Med 1995;162:268-9
   PubMedGoogle Scholar
• Cuffe MS, Califf RM, Adams KF Jr, Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7
   PubMed Web of Science ®Google Scholar
• Onorati F, Renxulli A, De Feo M, Perioperative enoximone infusion improves cardiac enzyme release after CABG. J Cardiothorac Vasc Anesth 2004;18:409-14
   PubMed Web of Science ®Google Scholar
• . Fleming GA, Murray KT, Yu C, Pretorius M. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008;118:1619-25
   PubMed Web of Science ®Google Scholar
• Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A; European Milrinone Multicenter Trial Group. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 2001;15:306-15
   PubMed Web of Science ®Google Scholar
• Sampson KJ, Terrenoire C, Cervantes DO, Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an IKs transgenic mouse. J Physiol 2008;586:627-37
   PubMed Web of Science ®Google Scholar
• Patterson E, Yu X, Huang S, Suppression of autonomic-mediated triggered firing in pulmonary vein preparations, 24 hours postcoronary artery ligation in dogs. J Cardiovasc Electrophysiol 2006;17:763-70
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91
   PubMed Web of Science ®Google Scholar
• Roden DM, Anderson ME. Proarrhythmia. Handb Exp Pharmacol 2006;171:73-97
   PubMedGoogle Scholar
• Aliot E, De Roy L, Capucci A, Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angeiol 2003;52:34-40
   PubMedGoogle Scholar
• Schreiber DH, DeFreest MS. Paroxysmal atrial fibrillation precipitated by amiodarone-induced thyrotoxicosis five months after cessation of therapy. J Emerg Med 2006;31:61-4
   PubMed Web of Science ®Google Scholar
• Kurt IH, Yigit T, Karademir BM. Atrial fibrillation due to late amiodarone-induced thyrotoxicosis. Clin Drug Investig 2008;28:527-31
   PubMed Web of Science ®Google Scholar
• Reithmann C, Dorwarth U, Dugas M, Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Eur Heart J 2003;24:1264-72
   PubMed Web of Science ®Google Scholar
• Shenasa M, Kus T, Fromer M, Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol 1988;62:403-7
   PubMed Web of Science ®Google Scholar
• Belhassen B, Viskin S, Laniado S. Sustained atrial fibrillation after conversion of paroxysmal reciprocating junctional tachycardia by intravenous verapamil. Am J Cardiol 1988;62:835-7
   PubMed Web of Science ®Google Scholar
• Doiuchi J, Hamada M, Ochi T, Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy. Clin Cardiol 1985;8:176-9
   PubMed Web of Science ®Google Scholar
• Isomoto S, Shimizu A, Knoe A, Effects of intravenous verapamil on atrial vulnerability. Jpn Circ J 1994;58:1-8
   PubMedGoogle Scholar
• Falk RH. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol 1998;82:10N-7
   PubMed Web of Science ®Google Scholar
• Ramanna H, Elvan A, Wittkampf FH, Increased dispersion and shortened refractoriness caused by verapamil in chronic atrial fibrillation. J Am Coll Cardiol 2001;37:1403-7
   PubMed Web of Science ®Google Scholar
• Strickberger SA, Man KC, Daoud EG, Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997;127:417-22
   PubMed Web of Science ®Google Scholar
• Kaney Y, Hannon S, Van-Tosh A, Schweitzer P. Adenosine-induced atrial fibrillation during pharmacologic stress testing: report of eight cases and review of the literature. Intern J Cardiol 2008;129:e15-17
   PubMed Web of Science ®Google Scholar
• Glatter KA, Cheng J, Dorostkar P, Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999;99:1034-40
   PubMed Web of Science ®Google Scholar
• Silverman AJ, Machado C, Baga JJ, Adenosine-induced atrial fibrillation. Am J Emerg Med 1996;14:300-1
   PubMed Web of Science ®Google Scholar
• McIntosh-Yellin NL, Drew BJ, Scheinman MM. Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia. J Am Coll Cardiol 1993;22:741-5
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
   PubMed Web of Science ®Google Scholar
• Crosson JE, Etheridge SP, Milstein S, Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children. Am J Cardiol 1994;15:155-60
   Google Scholar
• Cowell RP, Paul VE, Ilsley CD. Haemodynamic deterioration after treatment with adenosine. Br Heart J 1994;71:569-71
   PubMedGoogle Scholar
• Camaiti A, Pieralli F, Olivotto J, Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur J Emerg Med 2001;8:99-105
   PubMedGoogle Scholar
• Tamargo J, Caballero R, Gomez R, Pharmacology of potassium channels. Cardiovasc Res 2004;62:9-33
   PubMed Web of Science ®Google Scholar
• O'Nunain SO, Garratt C, Paul V, Effect of intravenous adenosine on human atrial and ventricular repolarisation. Cardiovasc Res 1992;26:939-43
   PubMed Web of Science ®Google Scholar
• Nanthakumar K, Plumb VJ, Epstein AE, Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation 2004;109:1226-9
   PubMed Web of Science ®Google Scholar
• Arentz T, Macle L, Kalusche D, “Dormant” pulmonary vein conduction revealed by adenosine after ostial radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2004;15:1041-7
   PubMed Web of Science ®Google Scholar
• Datino T, Macle L, Qi XY, Mechanisms by which adenosine restores conduction in dormant canine pulmonary veins. Circulation 2010;121:963-72
   PubMed Web of Science ®Google Scholar
• Datino T, Macle L, Chartier D, Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: a clinical-experimental correlation. Heart Rhythm 2011;8:1426-33
   PubMed Web of Science ®Google Scholar
• Tamargo J, Delpon E, Caballero R. The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf 2006;5:453-67
   PubMed Web of Science ®Google Scholar
• Massie BM, Shah NB, Pitt B, Packer M. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. Am Heart J 1996;132:130-6
   PubMed Web of Science ®Google Scholar
• Guzzetti S, Costantino G, Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation 2002;106:e40
   PubMed Web of Science ®Google Scholar
• Lainscak M, Dagres N, Filippatos GS, Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol 2008;128:311-15
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102:14-25
   PubMed Web of Science ®Google Scholar
• Dindogru A, Barcos M, Henderson ES, Wallace HJ Jr. Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol 1978;5:65-71
   PubMedGoogle Scholar
• Kilickap S, Barista I, Akgul E, Early and late arrhythmogenic effects of doxorubicin. South Med J 2007;100:262-5
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH, Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined modality paradigm. J Clin Oncol 2006;24:1072-8
   PubMed Web of Science ®Google Scholar
• Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991;9:192-3
   PubMed Web of Science ®Google Scholar
• Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988;13:41-6
   PubMed Web of Science ®Google Scholar
• Petrella V, Alciato P, Cantone PA, High-frequency supraventricular arrhythmias induced by a cisplatin-etoposide combination. Minerva Med 1989;80:305-7
   PubMedGoogle Scholar
• Lara PN Jr, Mack PC, Synold T, The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005;11:4444-50
   PubMed Web of Science ®Google Scholar
• Ifran A, Kaptan K, Beyan C. High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation. Am J Hematol 2005;80:247
   PubMed Web of Science ®Google Scholar
• Moreau P, Milpied N, Mahe B, Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003-6
   PubMed Web of Science ®Google Scholar
• Bischiniotis TS, Lafaras CT, Platogiannis DN, Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol 2005;46:324-9
   PubMedGoogle Scholar
• Tomkowski WZ, Wisniewska J, Szturmowicz M, Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 2004;12:53-7
   PubMed Web of Science ®Google Scholar
• Richards WG, Zellos L, Bueno R, Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006;24:1561-7
   PubMed Web of Science ®Google Scholar
• Illiano A, Barletta E, De Marino V, New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Anticancer Res 2000;20:3999-4003
   PubMed Web of Science ®Google Scholar
• Quezado ZM, Wilson WH, Cunnion RE, High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31-6
   PubMed Web of Science ®Google Scholar
• Kupari M, Volin L, Suokas A, Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990;5:91-8
   PubMed Web of Science ®Google Scholar
• Olivieri A, Corvatta L, Montanari M, Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant 1998;21:1049-53
   PubMed Web of Science ®Google Scholar
• Phillips GL, Meisenberg B, Reece DE, Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan:a phase I study. Biol Blood Marrow Transplant 2004;10:473-83
   PubMed Web of Science ®Google Scholar
• Feliz V, Saiyad S, Ramarao SM, Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011;34:356-9
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles R, Treleaven J, The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533-9
   PubMed Web of Science ®Google Scholar
• Mileshkin LR, Seymour JF, Wolf MM, Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stern cell transplantation for patients aged 60 years and older. Leuk Lymphoma 2005;45:1575-9
   Google Scholar
• Guglin M, Aljayeh M, Saiyad S, Introducing a new entity: chemotherapy-induced arrhythmia. Europace 2009;11:1579-86
   PubMed Web of Science ®Google Scholar
• Floyd JD, Nguyen DT, Lobins RL, Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685-96
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kallistratos MS, Kopterides P, Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134:75-82
   PubMed Web of Science ®Google Scholar
• Eskilsson J, Albertsson M, Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988;13:41-6
   PubMed Web of Science ®Google Scholar
• Jeremic B, Jevremovic S, Djuric L, Mijatovic L. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990;2:264-7
   PubMed Web of Science ®Google Scholar
• Ceyhan C, Meydan N, Barutca S, Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion. J Clin Pharm Ther 2004;29:267-71
   PubMed Web of Science ®Google Scholar
• Gridelli C, Cigolari S, Gallo C, MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001;31:277-84
   PubMed Web of Science ®Google Scholar
• Moscetti L, Ramponi S, Maccaglia C, Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy. Clin Ter 1998;149:377
   PubMedGoogle Scholar
• Lombardi D, Crivellari D, Scuderi C, Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 2004;90:285-8
   PubMed Web of Science ®Google Scholar
• Tavil Y, Arslan U, Okyay K, Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man. Onkologie 2007;30:253-5
   PubMed Web of Science ®Google Scholar
• Santini D, Tonini G, Abbate A, Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol 2000;11:479-81
   PubMed Web of Science ®Google Scholar
• Ciotti R, Belotti G, Facchi E, Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999;10:997
   PubMed Web of Science ®Google Scholar
• Ferrari D, Carbone C, Codeca C, Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer drugs 2006;17:359-61
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZS, Cunningham D, European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-24
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97
   PubMed Web of Science ®Google Scholar
• Lee RE, Lotze MT, Skibber JM, Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Fisher RI, Weiss G, Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-62
   PubMed Web of Science ®Google Scholar
• Margolin KA, Rayner AA, Hawkins MJ, Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98
   PubMed Web of Science ®Google Scholar
• White RL Jr, Schwartzentruber DJ, Guleria A, Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994;74:3212-22
   PubMed Web of Science ®Google Scholar
• Weiss RB, Grillo-Lopez AJ, Marsoni S, Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 1986;4:918-28
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S, Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205-13
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:655-8
   PubMed Web of Science ®Google Scholar
• Cassinotti A, Massari A, Ferrara E, New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol 2007;63:875-8
   PubMed Web of Science ®Google Scholar
• Dodd HJ, Tatnall FM, Sarkany I. Fast atrial fibrillation induced by treatment of psoriasis with azathioprine. BMJ 1985;291:706
   PubMed Web of Science ®Google Scholar
• Murphy G, Fulton RA, Keegan DA. Fast atrial fibrillation induced by azathioprine. BMJ 1985;291:1049
   Google Scholar
• Riccioni G, Bucciarelli V, Di Ilio E, Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: case report and review of the literature. Int J Immunopathol Pharmacol 2011;24:247-9
   PubMed Web of Science ®Google Scholar
• Palma M, Mancuso A, Grifalchi F, Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002;88:527-9
   PubMed Web of Science ®Google Scholar
• Oster MW, Rakowski TJ. Myocardial injury immediately following adriamycin administration. Med Pediatr Oncol 1981;9:463-5
   PubMedGoogle Scholar
• Montella L, Caraglia M, Addeo R, Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). Ann Hematol 2005;84:192-3
   PubMed Web of Science ®Google Scholar
• Zingler VC, Nabauer M, Jahn K, Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005;54:28-33
   PubMed Web of Science ®Google Scholar
• Mego M, Reckova M, Obertova J, Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007;18:1906-7
   PubMed Web of Science ®Google Scholar
• Olin RL, Desai SS, Fox K, Davidson R. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J 2007;13:211-112
   PubMed Web of Science ®Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231-47
   PubMed Web of Science ®Google Scholar
• Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Bellocci F, Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4
   PubMed Web of Science ®Google Scholar
• Chung MK, Martin DO, Sprecher D, C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91
   PubMed Web of Science ®Google Scholar
• Ciotti R, Belotti G, Facchi E, Sudden cardiopulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999;10:997
   PubMed Web of Science ®Google Scholar
• Merli GJ, Weitz H, Martin JH, Cardiac dysrhythmias associated with ophthalmic atropine. Arch Intern Med 1986;146:45-7
   PubMed Web of Science ®Google Scholar
• Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991;52:174-6
   PubMed Web of Science ®Google Scholar
• White WB, Wong SH. Rapid atrial fibrillation associated with trazodone hydrochloride. Arch Gen Psychiatry 1985;42:424
   PubMed Web of Science ®Google Scholar
• Low RA Jr, Fuller MA, Popli A. Clozapine-induced atrial fibrillation. J Clin Psychopharmacol 1998;18:170
   PubMed Web of Science ®Google Scholar
• Waters B, Joshi K, Flynn J. Olanzapine-Associated New-Onset Atrial Fibrillation. J Clin Psychopharmacol 2008;28:354-5
   PubMed Web of Science ®Google Scholar
• Yaylaci S, Tamer A, Kocayigit I, Gunduz H. Atrıal fıbrıllatıon due to olanzapine overdose. Clin Toxicol (Phila) 2011;49:440
   PubMed Web of Science ®Google Scholar
• Schneider RA, Lizer MH. Apparent seizure and atrial fibrillation associated with paliperidone. Am J Health Syst Pharm 2008;65:2122-5
   PubMed Web of Science ®Google Scholar
• Shaibani A, Fares S, Selam J, Lacosamide in painful diabetic neuropathy: an 18-week double blind placebo controlled trial. Clin J Pain 2009;10:818-28
   PubMed Web of Science ®Google Scholar
• DeGiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010;18:322-4
   PubMed Web of Science ®Google Scholar
• Morgan DR, Trimble M, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ 2000;321:275
   PubMed Web of Science ®Google Scholar
• Devadathan S, Gunning M. Atrial fibrillation following oral sumatriptan administration. Int J Cardiol 2006;107:112-13
   PubMed Web of Science ®Google Scholar
• Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anesth 2003;50:229-31
   PubMed Web of Science ®Google Scholar
• Havrilla PL, Kane-Gill SL, Verrico MM, Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother 2009;43:532-6
   PubMed Web of Science ®Google Scholar
• Kasinath NS, Malak O, Tetzlaff J. Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Can J Anesth 2003;50:229-31
   PubMed Web of Science ®Google Scholar
• Ardolino G, D'Adda E, Nobile-Orazio E. Recurrent atrial fibrillation after subcutaneous apomorphine. Parkinsonism Relat Disord 2008;14:173-4
   PubMed Web of Science ®Google Scholar
• Pratila MG, Pratilas V. Dysrhythmia occurring during epidural anesthesia with bupivacaine. Mt Sinai J Med 1982;49:130-2
   PubMed Web of Science ®Google Scholar
• Sueda S, Fukuda H, Watanabe K, Clinical characteristics and possible mechanism of paroxysmal atrial fibrillation induced by intracoronary injection of acetylcholine. Am J Cardiol 2001;88:570-3
   PubMed Web of Science ®Google Scholar
• Maister AH. Atrial fibrillation following physostigmine. Can Anaesth Soc J 1983;30:419-21
   PubMedGoogle Scholar
• Kiat H, Iskandrian AS, Villegas BJ, Arbutamine stress thallium-201 single-photon emission computed tomography using a computerized closed-loop delivery system: multicenter trial for evaluation of safety and diagnostic accuracy. The International Arbutamine Study Group. J Am Coll Cardiol 1995;26:1159-67
   PubMed Web of Science ®Google Scholar
• MacMahon JR. Atrial fibrillation and sympathomimetics (letter). J Pediatr 1974;84:613
   PubMed Web of Science ®Google Scholar
• Hayashi K, Minezaki KK, Narukawa M, Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. Jpn Heart J 1999;40:827-30
   PubMedGoogle Scholar
• Awan GM, Calderon E, Dawood G, Alpert MA. Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Sci 2000;320:69-71
   PubMed Web of Science ®Google Scholar
• Hahn IH, Hoffman RS. Aroused to atrial fibrillation? Am J Emerg Med 2000;18:642
   PubMed Web of Science ®Google Scholar
• Veloso HH, de Paola AAV. Atrial fibrillation after vardenafil therapy. Emerg Med J 2005;22:823
   PubMed Web of Science ®Google Scholar
• Frederiksen MC, Toig RM, Depp R III. Atrial fibrillation during hexoprenaline therapy for premature labor. Am J Obstet Gynecol 1983;145:108-9
   PubMed Web of Science ®Google Scholar
• Carson MP, Fisher AJ, Scorza WE. Atrial fibrillation in pregnancy associated with oral terbutaline. Obstet Gynecol 2002;100:1096-7
   PubMed Web of Science ®Google Scholar
• Lashgari S, Kueck AS, Oyelese Y. Atrial fibrillation in pregnancy associated with oral terbutaline therapy. Obstet Gynecol 2003;101:814
   PubMed Web of Science ®Google Scholar
• Parasuraman R, Gandhi MM, Liversedge NH. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion. BJOG 2006;113:844-5
   PubMed Web of Science ®Google Scholar
• Lau DH, Stiles MK, John B, Atrial fibrillation and anabolic steroid abuse. Int J Cardiol 2007;117:e86-7
   PubMedGoogle Scholar
• Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999;17:851-7
   PubMed Web of Science ®Google Scholar
• Liu T, Shehata M, Li G, Wang X. Androgens and atrial fibrillation: friends or foes? Int J Cardiol 2010;145:365-7
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
   PubMed Web of Science ®Google Scholar
• Bhuriya R, Singh M, Molnar J, Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Intern J Cardiol 2010;142:213-17
   PubMed Web of Science ®Google Scholar
• Pazianas M, Compston J, Huang CL. Atrial fibrillation and bisphosphonate therapy. J Bone Min Res 2010;25:2-10
   PubMed Web of Science ®Google Scholar
• Heckbert S, Li G, Cummings S, Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-31
   PubMed Web of Science ®Google Scholar
• Sorensen H, Christensen S, Mehnert F, Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-16
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with an oral bisphosphonate. J Intern Med 2009;265:581-92
   PubMed Web of Science ®Google Scholar
• Grosso A, Douglas I, Hingorani A, Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009;4:e4720
   PubMed Web of Science ®Google Scholar
• Hewitt RE, Lissina A, Green AE, The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;139:101-11
   PubMed Web of Science ®Google Scholar
• Jara M, Lanes SF, Wentworth C III, Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-60
   PubMed Web of Science ®Google Scholar
• Patane S, Marte F, La Rosa FC, La Rocca R. Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse. Int J Cardiol 2010;19:145: e74-6
   Google Scholar
• Poukkula A, Korhonen UR, Huikuri H, Linnaluoto M. Theophylline and salbutamolin combination in patients with obstructive pulmonary disease and cocurrent heart disease: effect on cardiac arrhythmias. J Intern Med 1989;226:229-34
   PubMed Web of Science ®Google Scholar
• Breeden CC, Safirstein BH. Albuterol and spacer-induced atrial fibrillation. Chest 1990;98
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Grogan DR, Baumgartner RA, Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008;87:319-28
   PubMed Web of Science ®Google Scholar
• Daubert GP, Mabasa VH, Leung VW, Aaron C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. J Med Toxicol 2007;3:56-60
   PubMedGoogle Scholar
• Varriale P, Ramaprasad S. Aminophylline induced atrial fibrillation. Pacing Clin Electrophysiol 1993;16:1953-5
   PubMed Web of Science ®Google Scholar
• Henderson A, Wright DM, Pond SM. Management of theophylline overdose patients in the intensive care unit. Anaesth Intensive Care 1992;20:56-62
   PubMed Web of Science ®Google Scholar
• Chazan R, Karwat K, Tyminska K, Cardiac arrhythmias as a result of intravenous infusions of theophylline in patients with airway obstruction. Int J Clin Pharmacol Ther 1995;33:170-5
   PubMed Web of Science ®Google Scholar
• Phillips GL, Meisenberg B, Reece DE, Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant 2004;10:473-83
   PubMed Web of Science ®Google Scholar
• Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30:175-7
   PubMed Web of Science ®Google Scholar
• LoVecchio FA. Atrial fibrillation following acute overdose with oral cyclosporine. Ann Pharmacother 2000;34:405
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28
   PubMed Web of Science ®Google Scholar
• Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J 2000;72:517-19
   PubMedGoogle Scholar
• Oteri A, Bussolini A, Sacchi M, A case of atrial fibrillation induced by inhaled fluticasone propionate. Pediatrics 2010;126:e1237-41
   PubMed Web of Science ®Google Scholar
• McCune KH, O'Brien CJ. Atrial fibrillation induced by ibuprofen overdose. Postgrad Med J 1993;69:325-6
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Giles FJ, Khouri I, Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol 2005;16:139-45
   PubMed Web of Science ®Google Scholar
• O'Driscoll BR. Supraventricular tachycardia caused by nebulised ipratropium bromide. Thorax 1989;44:312
   PubMed Web of Science ®Google Scholar
• McDermott MF, Nasr I, Rydman RJ, Comparison of two regimens of beta-adrenergics in acute asthma. J Med Syst 1999;23:269-79
   PubMedGoogle Scholar
• Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 2005;25:1271-6
   PubMed Web of Science ®Google Scholar
• Varkey S. Overdose of yohimbine. BMJ 1992;304:548
   PubMed Web of Science ®Google Scholar
• Stewart PM, Catterall JR. Chronic nicotine ingestion and atrial fibrillation. Br Heart J 1985;54:222-3
   PubMedGoogle Scholar
• Choragudi NL, Aronow WS, DeLuca AJ. Nicotine gum-induced atrial fibrillation. Heart Dis 2003;5:100-1
   PubMedGoogle Scholar
• Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. JAMA 1986;255:1018
   PubMed Web of Science ®Google Scholar
• Korantzopoulos P, Liu T, Papaioannides D, Atrial fibrillation and marijuana smoking. Int J Clin Pract 2008;62:308-13
   PubMed Web of Science ®Google Scholar
• Kirson LE, Wilson ME. Atrial fibrillation associated with intravenous fluorescein. Anesth Analg 1987;66:283
   PubMed Web of Science ®Google Scholar
• Rozental JM, Robins HI, Finlay J, ‘Eight-drugs-in-one-day' chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas. Cancer 1989;63:2475-81
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967-75
   PubMed Web of Science ®Google Scholar
• Knecht S, Oelschlager C, Duning T, Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-32
   PubMed Web of Science ®Google Scholar
• Dogukan A, Ilkay E, Poyrazoglu OK, Atrial fibrillation due to oral methylprednisolone in a patient with membranoproliferative glomerulonephritis. Acta Med (Hradec Kralove) 2008;51:63-4
   PubMedGoogle Scholar